Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Bob Lowenberg; Joachim Beck; Carlos Graux; Wim van Putten; Harry C. Schouten; Leo F. Verdonck; Augustin Ferrant; Pieter Sonneveld; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J. Biemond; Edo Vellenga; Dimitri Breems; Hilde de Muijnck; M Ron Schaafsma; Gregor E. G. Verhoef; Hartmut Doehner; Alois Gratwohl; Thomas Pabst; Gert Jan Ossenkoppele; Johan Maertens

doi:10.1182/blood-2009-10-246470

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Bob Lowenberg, Joachim Beck, Carlos Graux, Wim van Putten, Harry C. Schouten, Leo F. Verdonck, Augustin Ferrant, Pieter Sonneveld, Mojca Jongen-Lavrencic, Marie von Lilienfeld-Toal, Bart J. Biemond, Edo Vellenga, Dimitri Breems, Hilde de Muijnck, M Ron Schaafsma, Gregor E. G. Verhoef, Hartmut Doehner, Alois Gratwohl, Thomas Pabst, Gert Jan OssenkoppeleJohan Maertens

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	2586-2591
Journal	Blood
Volume	115
Issue number	13
DOIs	https://doi.org/10.1182/blood-2009-10-246470
Publication status	Published - 1 Apr 2010

Access to Document

10.1182/blood-2009-10-246470

Cite this

Lowenberg, B., Beck, J., Graux, C., van Putten, W., Schouten, H. C., Verdonck, L. F., Ferrant, A., Sonneveld, P., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biemond, B. J., Vellenga, E., Breems, D., de Muijnck, H., Schaafsma, M. R., Verhoef, G. E. G., Doehner, H., Gratwohl, A., Pabst, T., ... Maertens, J. (2010). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115(13), 2586-2591. https://doi.org/10.1182/blood-2009-10-246470

Lowenberg, Bob ; Beck, Joachim ; Graux, Carlos ; van Putten, Wim ; Schouten, Harry C. ; Verdonck, Leo F. ; Ferrant, Augustin ; Sonneveld, Pieter ; Jongen-Lavrencic, Mojca ; von Lilienfeld-Toal, Marie ; Biemond, Bart J. ; Vellenga, Edo ; Breems, Dimitri ; de Muijnck, Hilde ; Schaafsma, M Ron ; Verhoef, Gregor E. G. ; Doehner, Hartmut ; Gratwohl, Alois ; Pabst, Thomas ; Ossenkoppele, Gert Jan ; Maertens, Johan. / Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. In: Blood. 2010 ; Vol. 115, No. 13. pp. 2586-2591.

@article{17f9c6024f7248a89a27f84244b0c915,

title = "Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study",

author = "Bob Lowenberg and Joachim Beck and Carlos Graux and {van Putten}, Wim and Schouten, {Harry C.} and Verdonck, {Leo F.} and Augustin Ferrant and Pieter Sonneveld and Mojca Jongen-Lavrencic and {von Lilienfeld-Toal}, Marie and Biemond, {Bart J.} and Edo Vellenga and Dimitri Breems and {de Muijnck}, Hilde and Schaafsma, {M Ron} and Verhoef, {Gregor E. G.} and Hartmut Doehner and Alois Gratwohl and Thomas Pabst and Ossenkoppele, {Gert Jan} and Johan Maertens",

year = "2010",

month = apr,

day = "1",

doi = "10.1182/blood-2009-10-246470",

language = "English",

volume = "115",

pages = "2586--2591",

journal = "Blood",

issn = "0006-4971",

publisher = "The American Society of Hematology",

number = "13",

}

Lowenberg, B, Beck, J, Graux, C, van Putten, W, Schouten, HC, Verdonck, LF, Ferrant, A, Sonneveld, P, Jongen-Lavrencic, M, von Lilienfeld-Toal, M, Biemond, BJ, Vellenga, E, Breems, D, de Muijnck, H, Schaafsma, MR, Verhoef, GEG, Doehner, H, Gratwohl, A, Pabst, T, Ossenkoppele, GJ & Maertens, J 2010, 'Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study', Blood, vol. 115, no. 13, pp. 2586-2591. https://doi.org/10.1182/blood-2009-10-246470

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. / Lowenberg, Bob; Beck, Joachim; Graux, Carlos; van Putten, Wim; Schouten, Harry C.; Verdonck, Leo F.; Ferrant, Augustin; Sonneveld, Pieter; Jongen-Lavrencic, Mojca; von Lilienfeld-Toal, Marie; Biemond, Bart J.; Vellenga, Edo; Breems, Dimitri; de Muijnck, Hilde; Schaafsma, M Ron; Verhoef, Gregor E. G.; Doehner, Hartmut; Gratwohl, Alois; Pabst, Thomas; Ossenkoppele, Gert Jan; Maertens, Johan.

In: Blood, Vol. 115, No. 13, 01.04.2010, p. 2586-2591.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

AU - Lowenberg, Bob

AU - Beck, Joachim

AU - Graux, Carlos

AU - van Putten, Wim

AU - Schouten, Harry C.

AU - Verdonck, Leo F.

AU - Ferrant, Augustin

AU - Sonneveld, Pieter

AU - Jongen-Lavrencic, Mojca

AU - von Lilienfeld-Toal, Marie

AU - Biemond, Bart J.

AU - Vellenga, Edo

AU - Breems, Dimitri

AU - de Muijnck, Hilde

AU - Schaafsma, M Ron

AU - Verhoef, Gregor E. G.

AU - Doehner, Hartmut

AU - Gratwohl, Alois

AU - Pabst, Thomas

AU - Ossenkoppele, Gert Jan

AU - Maertens, Johan

PY - 2010/4/1

Y1 - 2010/4/1

U2 - 10.1182/blood-2009-10-246470

DO - 10.1182/blood-2009-10-246470

M3 - Article

VL - 115

SP - 2586

EP - 2591

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -